Pfizer Drops Cardiology Drug after Phase 3 Trials Failed
Pfizer is dropping one of the assets it picked up in the takeover of Array Bio Pharma, worth 11.4 billion dollars three years ago. After carrying out a phase 3 interim futility analysis, Big Pharma has decided to stop working on the cardiovascular disease candidate PF-07265803. With Array BioPharma kicking it off in 2018, Pfizer […]
Continue Reading